NCT03819153), secondary analyses of GLP-1RA CVOTs indicate that liraglutide [17], semaglutide [18], dulaglutide [25] and efpeglenatide [20] may reduce the relative risk of a composite kidney outcome, comprising new-onset macroalbuminuria, worsening kidney function, end-stage renal disease and renal death, by 1536%
The expected weight loss for semaglutide is a hot topic, especially as more people turn to these medications after struggling with diet and exercise alone
Some researchers create a simple tracking system in their phone with calendar reminders set for 28 days after opening each vial
Eriksson, L
The most common variant is UGT1A1*28 (rs8175347), a promoter polymorphism where the normal (TA)6 repeat in the TATA box is expanded to (TA)7
Inject Friday instead of Sunday